Browse approved medicines and investigational or experimental peptides.Keep human and preclinical evidence distinct from regulatory status.
Grades describe evidence for a specific claim. They are separate from regulatory approval.
Evidence describes a specific claim; approval applies to a medicine, use, and jurisdiction. Open each profile for its sources, limitations, and review status.
Also known as Tymlos, BA058
Synthetic analogue of human parathyroid hormone-related protein (PTHrP 1-34) approved for postmenopausal women and men with high fracture risk osteoporosis.
Also known as Scenesse, CUV1647, NDP-MSH
Alpha-MSH analogue implant (Scenesse) approved to increase pain-free light exposure in adults with erythropoietic protoporphyria; vitiligo is investigational.
Also known as Advanced Obesity Drug 9604, Tyr-hGH 177-191
Modified 16-amino-acid fragment of human growth hormone studied in Phase 2b obesity trials, where it failed to demonstrate significant weight reduction.
Also known as Acetyl Hexapeptide-3, Acetyl Hexapeptide-8, Ac-EEMQRR-NH2
Acetyl hexapeptide-8, a SNAP-25-mimicking cosmetic peptide. Small topical wrinkle trials; limited skin penetration; not a drug.
Also known as Body Protection Compound 157, PL 14736, Bepecin
A 15-amino-acid synthetic peptide studied in animal models of tendon, gut, and muscle healing. Lacks controlled human clinical trial evidence.
Also known as Vyleesi, PT-141
FDA-approved cyclic melanocortin receptor agonist indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Also known as CagriSema, cagrilintide-semaglutide
An investigational long-acting amylin analogue from Novo Nordisk, studied alone and with semaglutide (CagriSema) in phase 3 obesity and diabetes trials. Not FDA-approved.
Also known as Modified GRF 1-29, DAC:GRF, Tetrasubstituted GHRH
Synthetic growth hormone releasing hormone (1-29) analogue engineered for extended half-life; evaluated in early Phase 1/2 human trials.
Also known as PNB-0408, ATH-1001, Hexanoyl-Tyr-Ile-Ahx-NH2
An angiotensin IV-derived compound studied for memory in rodents only. A key mechanism paper was retracted; FDA reports no human exposure data.
Also known as Delta Sleep-Inducing Peptide, Emideltide
Delta sleep-inducing peptide, a 1970s rabbit-derived nonapeptide. Small, old insomnia trials gave conflicting results; no receptor identified.
Also known as Trulicity, LY2189265
Once-weekly GLP-1 receptor agonist (Trulicity) for type 2 diabetes; REWIND showed a modest drop in major cardiovascular events.
Also known as Forzinity, SS-31, MTP-131, Bendavia, Szeto-Schiller peptide
Mitochondria-targeted peptide given FDA accelerated approval (Forzinity) in 2025 for Barth syndrome, based on a very small trial; other trials were negative.
Also known as Epithalon, Ala-Glu-Asp-Gly, AGAG tetrapeptide
Synthetic tetrapeptide modeled on pineal extract epithalamin; investigated in rodent aging models for telomerase activation and pineal modulation.
Also known as Byetta, Bydureon, synthetic exendin-4
First-in-class synthetic exendin-4 GLP-1 receptor agonist approved by the FDA in 2005 for glycemic control in adult patients with type 2 diabetes.
Also known as Copper Peptide, Glycyl-L-histidyl-L-lysine copper, Copper tripeptide-1
Naturally occurring copper-binding tripeptide investigated for extracellular matrix remodeling, collagen synthesis, and topical skin health.
Also known as Acylated Ghrelin, Lenomorelin, Hunger hormone
28-amino-acid acylated gut hormone that activates the growth hormone secretagogue receptor (GHSR-1a) to drive appetite, feeding behavior, and pulsatile GH release.
Also known as Pralmorelin, KP-102, Growth hormone-releasing peptide-2
A synthetic GH-releasing hexapeptide (pralmorelin) used in Japan as a diagnostic test for GH deficiency. Not FDA-approved; FDA flags compounded injectable forms.
Also known as Growth hormone-releasing peptide-6, Growth hormone-releasing hexapeptide, SKF-110679
A synthetic six-amino-acid peptide that triggers growth hormone release via the ghrelin receptor. Used in research and diagnostic tests; not an approved medicine.
Also known as Glucose-Dependent Insulinotropic Polypeptide, Gastric Inhibitory Polypeptide
Endogenous 42-amino-acid incretin secreted by enteric K-cells; synergistic regulator of pancreatic beta-cell insulin secretion and adipose metabolism.
Also known as Glucagon-Like Peptide-1, GLP-1 (7-36) amide, Incretin hormone
Primary intestinal incretin hormone that stimulates glucose-dependent insulin secretion; native blueprint for the entire GLP-1 receptor agonist drug class.
Also known as GlucaGen, Baqsimi, Gvoke, Zegalogue
Endogenous 29-amino-acid pancreatic counter-regulatory hormone; FDA-approved emergency treatment for severe acute hypoglycemia.
Also known as GnRH, LHRH, Factrel, Lutrepulse
Synthetic copy of the brain hormone GnRH. Former U.S. human products (Factrel, Lutrepulse) are discontinued; pulsatile GnRH can restore ovulation in hypothalamic amenorrhea.
Also known as Examorelin, EP-23905
A synthetic GH-releasing hexapeptide related to GHRP-6. Studied in short human hormone and heart experiments; never an approved medicine.
Also known as Human Insulin, Regular Insulin, rDNA Insulin
Two-chain 51-amino-acid metabolic peptide hormone central to glucose uptake; essential lifesaving medicine for type 1 diabetes and advanced type 2 diabetes.
Also known as NNC 26-0161
Selective pentapeptide ghrelin receptor agonist stimulating pulsatile pituitary growth hormone release without significant cortisol elevation.
Also known as Kisspeptin-10, Kisspeptin-54, Metastin, KP-10, KISS1-derived peptides
Natural hormone that switches on the reproductive axis. Small phase 2 IVF studies used it to trigger egg maturation; no kisspeptin product is approved.
Also known as Lys-Pro-Val, alpha-MSH (11-13)
The C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone; studied in preclinical colitis models for NF-kappaB inhibition.
Also known as Somatuline, Somatuline Depot, BIM-23014
Long-acting somatostatin analogue approved for long-term acromegaly therapy and progression-free survival prolongation in gastroenteropancreatic NETs.
Also known as Larazotide acetate, AT-1001, AT1001
Oral gut-barrier peptide tested in celiac disease. Phase 2 results were mixed and the phase 3 trial was terminated by its sponsor in 2022.
Also known as Victoza, Saxenda
Once-daily GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with extensive long-term cardiovascular outcome trial data.
Also known as Adlyxin, Lyxumia, AVE0010, Soliqua 100/33
Once-daily GLP-1 receptor agonist for type 2 diabetes. Standalone Adlyxin is no longer marketed in the U.S.; lixisenatide remains available in Soliqua 100/33.
Also known as Cathelicidin antimicrobial peptide, hCAP-18 fragment
Endogenous 37-amino-acid amphipathic peptide providing innate mucosal defense; evaluated in early human trials for venous leg ulcer healing.
Also known as Palmitoyl Pentapeptide-4, Pal-KTTKS, Palmitoyl Pentapeptide-3
Palmitoyl pentapeptide-4, a collagen-fragment cosmetic peptide. Small, mostly industry-run skin studies; not an FDA-approved drug.
Also known as IBI362, LY3305677
A once-weekly GLP-1/glucagon dual agonist approved in China in 2025 for weight management and type 2 diabetes. Investigational and not FDA-approved in the U.S.
Also known as MT-II, Melanotan-II
Unapproved melanocortin agonist sold online for tanning. Only tiny 1990s human studies; case reports link it to melanoma, mole changes and priapism.
Also known as Mitochondrial open reading frame of the 12S rRNA type-c
A 16-amino-acid peptide encoded within mitochondrial DNA; studied in preclinical rodent models for metabolic homeostasis and AMPK activation.
Also known as Sandostatin, Sandostatin LAR, SMS 201-995
Synthetic cyclic somatostatin octapeptide analogue approved for acromegaly, severe diarrhea associated with metastatic carcinoid tumors, and VIPomas.
Also known as Pitocin, Syntocinon, alpha-hypophamine
Endogenous nonapeptide neurohypophysial hormone and FDA-approved medicine for medical labor induction and postpartum uterine hemorrhage control.
Also known as ALT-801
An investigational once-weekly GLP-1/glucagon dual agonist from Altimmune. Phase 2 trials show liver-fat reduction and MASH resolution; a phase 3 MASH trial is recruiting.
Also known as PYY, PYY (3-36), Pancreatic Peptide YY3-36
Postprandially secreted enteroendocrine L-cell peptide that acts as an ileal brake via central Y2 receptors to suppress appetite and slow gastric emptying.
Also known as Symlin, SymlinPen
FDA-approved synthetic analogue of human amylin used as mealtime adjunct therapy with insulin for glycemic regulation in type 1 and type 2 diabetes.
Also known as LY3437943
An investigational once-weekly GIP, GLP-1 and glucagon receptor agonist from Eli Lilly. Phase 3 obesity and diabetes trials report large weight loss; not FDA-approved.
Also known as Tuftsin analogue TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro
Synthetic heptapeptide tuftsin derivative studied in Russian clinical cohorts for generalized anxiety disorder; unapproved in the US and Europe.
Also known as Ozempic, Wegovy, Rybelsus
Long-acting GLP-1 receptor agonist proven in large Phase 3 RCTs for type 2 diabetes glycemic control, obesity weight reduction, and cardiovascular risk reduction.
Also known as Heptapeptide Semax, ACTH (4-7) Pro-Gly-Pro
Synthetic ACTH fragment analogue developed and clinically registered in Russia for stroke and cognitive recovery; unapproved by FDA or EMA.
Also known as Geref, GHRH(1-29)NH2, GRF(1-29)NH2
A 29-amino-acid fragment of GHRH. It was FDA-approved as Geref for pediatric GH deficiency and testing, then discontinued in 2008 for reasons unrelated to safety.
Also known as Imcivree, RM-493
MC4 receptor agonist (Imcivree) approved only for obesity from POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome or acquired hypothalamic obesity.
Also known as Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-3, Acetyl Octapeptide-1
Acetyl octapeptide-3, a longer Argireline-type cosmetic peptide. Efficacy claims rest on supplier data; no standalone peer-reviewed human trials.
Also known as BI 456906
An investigational once-weekly glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim, in phase 3 for obesity and MASH. Not FDA-approved.
Also known as Thymosin Beta-4 fragment, Tβ4 fragment, LKKTETQ
Synthetic peptide fragment modeled on Thymosin Beta-4; investigated in preclinical assays for actin sequestering, angiogenesis, and cell migration.
Also known as Forteo, rhPTH (1-34)
Recombinant human parathyroid hormone fragment (1-34) acting as an anabolic bone agent approved for severe osteoporosis with high fracture risk.
Also known as Egrifta, Egrifta SV, TH9507
FDA-approved stabilized GHRH analogue indicated for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
Also known as Thymalfasin, Zadaxin, Thymosin α1, Tα1, Ta1
Immune-signalling peptide sold as Zadaxin outside the U.S. A large sepsis trial found no survival benefit and hepatitis B evidence is low certainty.
Also known as Mounjaro, Zepbound, LY3298176
Dual GIP and GLP-1 receptor co-agonist approved by FDA for type 2 diabetes and chronic weight management following SURPASS and SURMOUNT clinical trials.
Also known as Vasostrict, Arginine Vasopressin, AVP, Antidiuretic Hormone
Endogenous peptide hormone regulating osmotic balance and vascular resistance; FDA-approved for increasing blood pressure in vasodilatory shock.
Also known as Aviptadil, Vasoactive intestinal polypeptide, RLF-100, Zyesami, Invicorp (aviptadil with phentolamine)
Natural neuropeptide; its synthetic form aviptadil failed a phase 3 COVID-19 trial. Used with phentolamine for erectile dysfunction outside the U.S.
Try a different name, research area or evidence level.
